Aprogen Biologics

Aprogen Biologics operates a pharmaceutical division and a biologics division; the pharmaceutical unit produces generic drugs, while the biologics unit manufactures antibody drugs using perfusion culture at its Osong plant in Chungbuk province.

Since its founding in 1960, the company diversified its structure in 2022 by merging with a firm holding biopharmaceutical production technology and bringing a semiconductor equipment parts maker under its umbrella as a subsidiary.

Through R&D collaboration with its parent company Aprogen, it is commercializing biosimilars and working to improve its profit structure in the CMO and CDMO segments.

Its Remicade (infliximab) biosimilar has obtained marketing approval in Japan and Latin America and completed Phase 3 trials, its Rituxan (rituximab) biosimilar is preparing for Phase 1, and its Herceptin (trastuzumab) biosimilar has completed Phase 1 and is preparing for EU marketing approval.

Its Humira (adalimumab) biosimilar AP-096 has completed process validation with parent Aprogen, and clinical sample production using the Osong plant's 2,000-liter perfusion bioreactor was also successfully completed.

In its CDMO business, the company is building sales organizations targeting Japanese and European biopharmaceutical firms to move beyond producing biosimilars only for its affiliate and secure external customers; the Osong plant houses four 2,000-liter perfusion production facilities described as among the world's largest of their kind.

Its controlling shareholder, Aprogen, has continued to provide funding support through rights offerings and convertible bonds.

Consolidated revenue in 2025 was KRW 73.2bn, fluctuating from KRW 65.2bn in 2022, KRW 87.4bn in 2023, and KRW 67.4bn in 2024.

Operating loss deepened from KRW 5.4bn in 2022 to KRW 57.5bn in 2023, KRW 52.8bn in 2024, and KRW 60.4bn in 2025, marking a third consecutive year of losses exceeding KRW 50bn, with the operating margin worsening to -82.4% in 2025 from -78.4% in 2024.

Net income attributable to owners swung from a profit of KRW 7.8bn in 2022 to losses of KRW 118.3bn in 2023, KRW 105.0bn in 2024, and KRW 170.3bn in 2025, the largest loss of the past four years.

Quarterly, the second quarter of 2025 stood out with revenue of KRW 14.9bn, an operating loss of KRW 18.0bn, and a notably large net loss of KRW 66.9bn attributable to owners, followed by the third quarter's revenue of KRW 21.1bn, operating loss of KRW 10.7bn, and net loss of KRW 24.4bn, and the fourth quarter's revenue of KRW 20.4bn, operating loss of KRW 16.0bn, and net loss of KRW 36.0bn.

Entering 2026, the first quarter showed revenue of KRW 21.6bn, operating loss of KRW 13.6bn, and a markedly narrower net loss of KRW 3.9bn, but the second quarter saw revenue rise to KRW 23.1bn while the operating loss widened again to KRW 17.5bn and the net loss to KRW 14.0bn, reflecting significant quarter-to-quarter volatility.

Revenue has shown a gradual uptrend, staying in the low-20-billion-won range for four straight quarters since the third quarter of 2025, while operating losses have persisted in the KRW 10-18bn range each quarter without meaningful improvement.

On the balance sheet, total equity fell sharply to KRW 277.6bn (owners' equity of KRW 207.8bn) at end-2025 from KRW 378.7bn (owners' equity of KRW 378.5bn) at end-2024, while the debt ratio surged from 34.6% in 2022 to 59.9% in 2023, 56.1% in 2024, and 111.5% in 2025.

Operating cash flow has also been negative for four consecutive years since 2022, coming in at negative KRW 38.2bn in 2025, underscoring continued cash burn.

Rising global demand for biologic drugs and the ripple effects of the U.S. push for biosecurity legislation are spurring Korean pharmaceutical and biotech firms to enter the CDMO business, with relatively high margins emerging as a new revenue source. Global regulatory easing trends, including the U.S.

FDA and EU EMA advancing guideline revisions to simplify biosimilar development procedures, are also creating a favorable environment for the industry.

The domestic CDMO market is led by large-capacity players such as Samsung Biologics and Lotte Biologics, meaning Aprogen Biologics approaches the market with relatively smaller production capacity and a specialized perfusion culture technology.

A strength of the Osong plant is its hybrid infrastructure capable of running both perfusion and Fed-Batch processes, and it has adopted a laboratory information management system (LIMS) also used by Bayer, DuPont, and Samsung Biologics to meet data integrity requirements.

However, in terms of track record, the company has so far relied mainly on producing biosimilars for its affiliate Aprogen, and its first commercial contract with an external global customer has not yet been clearly confirmed, leaving reference-building a challenge versus larger CDMO peers.

In the biosimilar segment, the company targets replacement demand arising from patent expirations of originator drugs such as Remicade, Herceptin, Rituxan, and Humira, though this market itself remains competitive among numerous domestic and global players.

The company has been building a 180,000-liter fifth plant in anticipation of rising demand for biologics, stating that total capacity at the Osong complex would rise to 784,000 liters upon completion.

On the CDMO sales front, it has stated plans to build dedicated sales organizations targeting Japanese and European biopharmaceutical companies and to consider further capacity expansion once customer demand becomes concrete.

In its biosimilar pipeline, the company said its Humira biosimilar AP-096 completed process validation and clinical sample production with its parent, achieving commercial-scale production capability, with plans to extend this technology platform to follow-on pipeline candidates.

Its Herceptin biosimilar is in the EU marketing-approval preparation stage, and its Rituxan biosimilar is preparing to enter Phase 1, meaning subsequent approval timelines will need to be confirmed step by step.

Company and parent officials have stated a goal of becoming a comprehensive global biotech firm by expanding global licensing deals and CMO/CDMO orders.

However, the signing of a first commercial contract with an external customer has been described as "imminent" on multiple occasions without yet being confirmed through a specific contract disclosure, meaning whether and when such an order materializes will be a key determinant of future earnings improvement.